Towards a chemotherapy-free future in breast cancer?
Recent studies support treatment optimisation for improving patients’ quality of life, but its implementation in clinical practice remains limited
Chemotherapy-free adjuvant treatment preserves quality of life in HER2-positive early breast cancer
A pathological complete response-guided approach enables treatment optimisation in a selected population with HER2-positive breast cancer in the PHERGain-2 study
SERD therapy demonstrates robust anti-proliferative activity in young patients with ER-positive/HER2-negative early breast cancer
Encouraging results with giredestrant support the future use of SERD-based endocrine strategies in this setting
Customised app shows promise for monitoring prostate cancer patients in real-time
A pilot study reports high levels of acceptance and compliance despite an older patient population
Why AI-powered trial matching alone will not fix oncology trial recruitment
AI-powered trial matching helps identify relevant trials faster, but recruitment often fails beyond the algorithm. Limited cross-site trial discovery, outdated recruitment information and fragmented referral pathways continue to prevent potentially eligible patients from participating in relevant trials.
Counting lines of therapy counts: ESMO leads the way of standardisation
A new ESMO consensus-driven document provides definitions, formats and minimum required data to uniform enumeration and reporting of prior lines of therapy across solid tumours
Rare cancer patients still have limited access to personalised care in Europe
Despite advances in molecular profiling, only a small fraction of patients with actionable alterations receive matched targeted therapies or immunotherapies
Can AI chatbots effectively support patients with cancer during treatments?
Early findings suggest potential benefits in symptom monitoring, but highlight usability challenges and added burden on clinical workflows
Optimising cancer care to improve clinical outcomes and sustainability
From chronotherapy to immunotherapy resistance, refining when and for whom treatments work is becoming central to making oncology sustainable
CTLA-4 targeting leads to improved overall survival in NSCLC progressing on immunotherapy
Early phase III trial results signal a much-needed chemotherapy-free advance with gotistobart in a setting where therapeutic choices are limited